Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000993006 | SCV001145679 | uncertain significance | not provided | 2019-06-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000993006 | SCV002248285 | likely pathogenic | not provided | 2023-02-28 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 158 of the SLC12A3 protein (p.Arg158Trp). This variant is present in population databases (no rsID available, gnomAD 0.002%). This missense change has been observed in individual(s) with Gitelman syndrome (PMID: 31285285). ClinVar contains an entry for this variant (Variation ID: 805471). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC12A3 protein function. This variant disrupts the p.Arg158 amino acid residue in SLC12A3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12112667, 21415153, 25852896, 30413979). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Natera, |
RCV001832310 | SCV002089326 | uncertain significance | Familial hypokalemia-hypomagnesemia | 2021-03-13 | no assertion criteria provided | clinical testing |